SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection

International Journal of Molecular Sciences

Niraj Lodhi¹  Rubi Singh²  Quaiser Saquib³  Satya Prakash Rajput⁴ 

[1] Clinical Research (Research and Development Division) miRNA Analytics LLC, Harlem Bio-Space, New York, NY 10027, USA;Department of Pharmacology, Weill Cornell Medicine, New York, NY 10065, USA;Department of Zoology, College of Sciences, King Saud University, Riyadh 12372, Saudi Arabia;School of Life Sciences, Warwick University, Coventry CV47AL, UK;

关键词: SARS-CoV-2;    ACE2;    TMPRSS2;    p53;    interferon;    transcription;   

DOI  :  10.3390/ijms22168660

来源: DOAJ

【 摘 要 】

Human ACE2 and the serine protease TMPRSS2 of novel SARS-CoV-2 are primary entry receptors in host cells. Expression of these genes at the transcriptional level has not been much discussed in detail. The ISRE elements of the ACE2 promoter are a binding site for the ISGF3 complex of the JAK/STAT signaling pathway. TMPRSS2, including IFNβ, STAT1, and STAT2, has the PARP1 binding site near to TSS either up or downstream promoter region. It is well documented that PARP1 regulates gene expression at the transcription level. Therefore, to curb virus infection, both promoting type I IFN signaling to boost innate immunity and prevention of virus entry by inhibiting PARP1, ACE2 or TMPRSS2 are safe options. Most importantly, our aim is to attract the attention of the global scientific community towards the codon 72 Single Nucleotide Polymorphism (SNP) of p53 and its underneath role in the innate immune response against SARS-CoV-2. Here, we discuss codon 72 SNP of human p53′s role in the different innate immune response to restrict virus-mediated mortality rate only in specific parts of the world. In addition, we discuss potential targets and emerging therapies using bioengineered bacteriophage, anti-sense, or CRISPR strategies.

【 授权许可】

Unknown